Total body skin examination increases squamous cell carcinoma detection: a retrospective cohort study.
- 作者列表："Ali Z","Todd PM
:Squamous cell carcinomas (SCCs) have the potential for local tissue destruction and metastasis. The risk of complications increases if the lesion is not diagnosed and excised in a timely manner. Total body skin examination (TBSE) has been reported to increase melanoma detection; the objective of this study was to determine if it also increases SCC detection. Analysis of 469 SCCs diagnosed at a UK tertiary centre showed that 6.8% of these were detected incidentally and not from the index lesion that prompted referral. These incidentally detected SCCs tended to represent early disease, and therefore carried lower risk of complications. Our findings suggest that full skin checks may increase the number of SCCs detected, and at an earlier stage of disease. Therefore, we encourage the use of TBSE in all dermatology outpatient appointments, and make suggestions as to how to incorporate it into the limited time available in dermatology clinics.
: 鳞状细胞癌 (scc) 具有局部组织破坏和转移的潜力。如果不及时诊断和切除病变，并发症的风险增加。据报道，全身皮肤检查 (TBSE) 增加了黑色素瘤的检测; 本研究的目的是确定它是否也增加了SCC的检测。对英国一家三级中心诊断的 469 例scc的分析显示，其中 6.8% 例是偶然检测到的，而不是来自提示转诊的指数病变。这些偶然检测到的scc往往代表早期疾病，因此具有较低的并发症风险。我们的研究结果表明，全面的皮肤检查可能会增加检测到的scc数量，并且在疾病的早期阶段。因此，我们鼓励在所有皮肤科门诊预约中使用TBSE，并就如何将其纳入皮肤科门诊可用的有限时间提出建议。
METHODS::Blue rubber bleb naevus syndrome (BRBNS) is an extremely rare venous malformation that often manifests as multiple haemangioma-like lesions in the skin and gastrointestinal tract. The drug sirolimus plays a key role in the signalling pathway of angiogenesis and subsequent development of BRBNS and its use has been described in several case reports. We present a case series of four patients with BRBNS who exhibited good treatment response to sirolimus. All four patients were administered oral sirolimus at doses of 1.0-1.5 mg/m2 /day with a target drug level of 5-10 ng/mL and median treatment duration of 20 months. All patients had a reduction in the size of the lesions and a normalization of coagulopathy with tolerable drug adverse reactions at follow-up. Sirolimus may be effective and safe in paediatric patients with BRBNS. Further prospective studies are suggested to evaluate the long-term effectiveness of this drug.
METHODS:BACKGROUND:Human papillomavirus (HPV) infections are associated with common dermatologic and nondermatologic diseases. Although HPV vaccines are well established as preventive measures for genital warts and cervical neoplasia, their use as therapeutic agents deserves greater attention. OBJECTIVE:To evaluate the use of HPV vaccine(s) as a treatment modality for cutaneous and/or mucosal disease. METHODS:A primary literature search using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines was conducted in January 2019 by using the PubMed and Cochrane databases. RESULTS:A total of 63 articles with 4439 patients were included. The majority of patients with cutaneous warts, recurrent respiratory papillomatosis, and squamous and basal cell carcinomas were successfully treated with HPV vaccination. Preliminary data on patients with pre-existing anogenital warts, cervical intraepithelial neoplasia, anal intraepithelial neoplasia, and vulvar intraepithelial neoplasia is promising. LIMITATIONS:This review was limited by the lack of controls, patients' previous HPV vaccination status, and publication bias. CONCLUSION:The commercially available three-dose, quadrivalent HPV vaccine is a potential therapeutic option for the treatment of cutaneous warts, recurrent respiratory papillomatosis, and squamous and basal cell carcinomas. Noncommercially available HPV vaccines demonstrate therapeutic response for treating anogenital warts, cervical intraepithelial neoplasia, anal intraepithelial neoplasia, and vulvar intraepithelial neoplasia. The vaccine's efficacy as an adjunct therapy for HPV-associated cutaneous and/or mucosal disease warrants further exploration.
METHODS::Our understanding of melanoma precursors and progression to melanoma has developed as a result of advances in the field of molecular diagnostics. We now better understand the potential for genetic heterogeneity within a single lesion. Combined tumors can pose a diagnostic challenge when deciding the line between benign and malignant, which in turn has direct implications for patient management. Primary cilia (PC) are ubiquitous sensory organelles that have essential functions in cellular proliferation, differentiation, and development. The ciliation index (percentage of ciliated melanocytes) has been shown to reliably differentiate melanoma, which fail to ciliate, from melanocytic nevi, which retain PC. We therefore analyzed the potential for using the ciliation index to differentiate benign and malignant components in combined melanocytic lesions. We collected patient samples (n = 10) of unequivocal combined lesions with both melanoma and associated nevus components. Melanocytes were highlighted with SOX10 and costained with gamma-Tubulin and acetylated alpha-Tubulin to highlight the basal body and cilium, respectively. The number of melanocytes retaining cilia under high-power microscopy was examined. The melanoma component had average of 4% ciliation (SD: 7%), whereas the associated nevus component was significantly higher with 59% ciliation (SD: 17%). These data show that PC may be a reliable means of distinguishing benign from malignant components within a single tumor. The ciliation index may be a helpful tool in distinguishing challenging cases of combined lesions of melanoma in situ with a dermal nevus component from invasive melanoma, thus promoting improved staging and clinical management.